MAXIVAX

MaxiVAX is a clinical-stage biotechnology company advancing patient-specific immunomodulatory strategies for the treatment of cancers. The company was founded in 2005 by Prof. Bernard Mach (ex-University of Geneva & Co-founder of Biogen, Founder of NovImmune), Prof. Nicolas Mach (Oncology, HUG in Geneva), and Me. Clarence Peter (Kellerhals Carrard), and has its Headquarters at the Campus Biotech Innovation Park in Geneva, Switzerland. MaxiVAX is dedicated to efficiently progressing potential best-in-class anti-cancer immunotherapies to address significant unmet medical needs and improve outcomes for people with difficult-to-treat cancer... MaxiVAXSA, a private Swiss clinical-stage biotech company developing novel anti-cancer vaccines, announced today that it had been awarded a European Commission grant of 2,785,000, thanks to the Horizon 2020EIC Accelerator Programme.MaxiVAX was among 94 funded projects out of 2,015 applicants, thereby ranking among the top 4% of high-tech..

Also known as: MaxiVAX SA